{"id":16880,"date":"2026-03-27T15:12:46","date_gmt":"2026-03-27T18:12:46","guid":{"rendered":"https:\/\/fenati.org.br\/?p=16880"},"modified":"2026-03-27T17:57:49","modified_gmt":"2026-03-27T20:57:49","slug":"brasil-producao-imunoterapia-40-tipos-de-cancer","status":"publish","type":"post","link":"https:\/\/homolog.fenati.org.br\/en\/brasil-producao-imunoterapia-40-tipos-de-cancer\/","title":{"rendered":"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer"},"content":{"rendered":"<p><strong>Imunoterapia &#8211;<\/strong> O governo federal anunciou, na quinta-feira (26), uma parceria que pode transformar o tratamento do c\u00e2ncer no Brasil. O acordo envolve o <a href=\"https:\/\/pt.wikipedia.org\/wiki\/Minist%C3%A9rio_da_Sa%C3%BAde_(Brasil)\" target=\"_blank\" rel=\"noopener\">Minist\u00e9rio da Sa\u00fade<\/a>, o Instituto Butantan e a farmac\u00eautica MSD, com foco na produ\u00e7\u00e3o nacional do pembrolizumabe, uma imunoterapia aprovada para quase 40 tipos diferentes de c\u00e2ncer.<\/p>\n<p>A iniciativa prev\u00ea a transfer\u00eancia de tecnologia para o pa\u00eds, estrat\u00e9gia que deve reduzir custos e ampliar o acesso ao medicamento no Sistema \u00danico de Sa\u00fade (SUS). Hoje, o uso do pembrolizumabe na rede p\u00fablica ainda \u00e9 limitado, principalmente devido ao alto custo da terapia.<\/p>\n<p><a href=\"https:\/\/fenati.org.br\/trabalhadoras-gravidas-ganham-direito-a-estabilidade\/\" target=\"_blank\" rel=\"noopener\"><strong>LEIA: Trabalhadoras tempor\u00e1rias gr\u00e1vidas ganham direito \u00e0 estabilidade<\/strong><\/a><\/p>\n<p>Segundo o g1, uma \u00fanica sess\u00e3o do tratamento pode chegar a cerca de R$ 97 mil na rede privada. Como o medicamento \u00e9 administrado de forma cont\u00ednua, o custo total pode ultrapassar centenas de milhares de reais ao longo do tratamento.<\/p>\n<p>Para especialistas, o pre\u00e7o elevado \u00e9 um dos principais entraves para a expans\u00e3o da imunoterapia no sistema p\u00fablico. Em entrevista ao g1, Stephen Stefani, oncologista do grupo Oncocl\u00ednicas e da Americas Health Foundation, afirma que o descompasso entre custo e financiamento dificulta a amplia\u00e7\u00e3o do acesso no SUS.<\/p>\n<p><strong>Como funciona a imunoterapia<\/strong><\/p>\n<p>Diferentemente da quimioterapia tradicional, que atua diretamente na destrui\u00e7\u00e3o das c\u00e9lulas tumorais, a imunoterapia age estimulando o sistema imunol\u00f3gico do pr\u00f3prio paciente a combater o c\u00e2ncer.<\/p>\n<p>Em muitos casos, as c\u00e9lulas cancer\u00edgenas desenvolvem mecanismos para escapar da defesa do organismo. Um dos principais envolve prote\u00ednas que funcionam como uma esp\u00e9cie de \u201cfreio\u201d das c\u00e9lulas de defesa.<\/p>\n<p>Os medicamentos imunoter\u00e1picos atuam justamente bloqueando esses mecanismos, permitindo que o sistema imunol\u00f3gico volte a reconhecer e atacar o tumor.<\/p>\n<p>O pembrolizumabe se destaca por ter uma das maiores listas de indica\u00e7\u00f5es aprovadas entre as imunoterapias, com autoriza\u00e7\u00e3o para uso em 40 tipos de c\u00e2ncer no Brasil. O medicamento j\u00e1 possui registro na Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) e \u00e9 amplamente utilizado na rede privada e por planos de sa\u00fade.<\/p>\n<p>Essa abordagem representa um avan\u00e7o importante na oncologia. Em determinados tipos de c\u00e2ncer, pode aumentar a sobrevida dos pacientes e melhorar a qualidade de vida, embora os resultados variem conforme o tipo de tumor.<\/p>\n<p><strong>Acesso ainda limitado no SUS<\/strong><\/p>\n<p>Apesar dos avan\u00e7os, o acesso \u00e0 imunoterapia no SUS ainda \u00e9 restrito. Atualmente, esse tipo de tratamento est\u00e1 dispon\u00edvel no sistema p\u00fablico apenas para casos de melanoma avan\u00e7ado.<\/p>\n<p>Para outros tipos de c\u00e2ncer, como pulm\u00e3o, mama, es\u00f4fago e colo do \u00fatero, a incorpora\u00e7\u00e3o da imunoterapia ainda depende de an\u00e1lise da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (Conitec).<\/p>\n<p>De acordo com o Minist\u00e9rio da Sa\u00fade, a decis\u00e3o de incluir novas terapias no sistema p\u00fablico considera n\u00e3o apenas os benef\u00edcios cl\u00ednicos, mas tamb\u00e9m o impacto financeiro para o SUS.<\/p>\n<p>&nbsp;<\/p>\n<p><em><strong>(Com informa\u00e7\u00f5es de Olhar Digital)<\/strong><\/em><\/p>\n<p><em><strong>(Foto: Reprodu\u00e7\u00e3o\/Freepik\/rawpixel.com)<\/strong><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Produ\u00e7\u00e3o nacional do pembrolizumabe deve ampliar acesso \u00e0 imunoterapia e reduzir custos no sistema p\u00fablico de sa\u00fade<\/p>","protected":false},"author":16,"featured_media":16882,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[13],"class_list":["post-16880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","tag-sindical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer - FENATI<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer - FENATI\" \/>\n<meta property=\"og:description\" content=\"Produ\u00e7\u00e3o nacional do pembrolizumabe deve ampliar acesso \u00e0 imunoterapia e reduzir custos no sistema p\u00fablico de sa\u00fade\" \/>\n<meta property=\"og:url\" content=\"https:\/\/homolog.fenati.org.br\/en\/brasil-producao-imunoterapia-40-tipos-de-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"FENATI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/feittinf\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T18:12:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-27T20:57:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2026\/03\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pedro Carneiro\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FederacaoTiBR\" \/>\n<meta name=\"twitter:site\" content=\"@FederacaoTiBR\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pedro Carneiro\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/\"},\"author\":{\"name\":\"Pedro Carneiro\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#\\\/schema\\\/person\\\/9ec09616199ae378090b2808cc903eae\"},\"headline\":\"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer\",\"datePublished\":\"2026-03-27T18:12:46+00:00\",\"dateModified\":\"2026-03-27T20:57:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/\"},\"wordCount\":525,\"publisher\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/homolog.fenati.org.br\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg\",\"keywords\":[\"sindical\"],\"articleSection\":[\"Not\u00edcias\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/\",\"url\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/\",\"name\":\"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer - FENATI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/homolog.fenati.org.br\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg\",\"datePublished\":\"2026-03-27T18:12:46+00:00\",\"dateModified\":\"2026-03-27T20:57:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/homolog.fenati.org.br\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg\",\"contentUrl\":\"https:\\\/\\\/homolog.fenati.org.br\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg\",\"width\":1200,\"height\":630,\"caption\":\"brasil-producao-imunoterapia-40-tipos-de-cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/brasil-producao-imunoterapia-40-tipos-de-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/homolog.fenati.org.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#website\",\"url\":\"https:\\\/\\\/homolog.fenati.org.br\\\/\",\"name\":\"FEITTINF\",\"description\":\"Federa\u00e7\u00e3o Nacional dos Trabalhadores em Tecnologia da\u00a0Informa\u00e7\u00e3o\",\"publisher\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/homolog.fenati.org.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#organization\",\"name\":\"FEITTINF\",\"url\":\"https:\\\/\\\/homolog.fenati.org.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/homolog.fenati.org.br\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/logo_300x50.png\",\"contentUrl\":\"https:\\\/\\\/homolog.fenati.org.br\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/logo_300x50.png\",\"width\":350,\"height\":50,\"caption\":\"FEITTINF\"},\"image\":{\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/feittinf\",\"https:\\\/\\\/x.com\\\/FederacaoTiBR\",\"https:\\\/\\\/www.instagram.com\\\/feittinf\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/homolog.fenati.org.br\\\/#\\\/schema\\\/person\\\/9ec09616199ae378090b2808cc903eae\",\"name\":\"Pedro Carneiro\",\"url\":\"https:\\\/\\\/homolog.fenati.org.br\\\/en\\\/author\\\/pedro-carneiro\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer - FENATI","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer - FENATI","og_description":"Produ\u00e7\u00e3o nacional do pembrolizumabe deve ampliar acesso \u00e0 imunoterapia e reduzir custos no sistema p\u00fablico de sa\u00fade","og_url":"https:\/\/homolog.fenati.org.br\/en\/brasil-producao-imunoterapia-40-tipos-de-cancer\/","og_site_name":"FENATI","article_publisher":"https:\/\/www.facebook.com\/feittinf","article_published_time":"2026-03-27T18:12:46+00:00","article_modified_time":"2026-03-27T20:57:49+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2026\/03\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg","type":"image\/jpeg"}],"author":"Pedro Carneiro","twitter_card":"summary_large_image","twitter_creator":"@FederacaoTiBR","twitter_site":"@FederacaoTiBR","twitter_misc":{"Written by":"Pedro Carneiro","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#article","isPartOf":{"@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/"},"author":{"name":"Pedro Carneiro","@id":"https:\/\/homolog.fenati.org.br\/#\/schema\/person\/9ec09616199ae378090b2808cc903eae"},"headline":"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer","datePublished":"2026-03-27T18:12:46+00:00","dateModified":"2026-03-27T20:57:49+00:00","mainEntityOfPage":{"@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/"},"wordCount":525,"publisher":{"@id":"https:\/\/homolog.fenati.org.br\/#organization"},"image":{"@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2026\/03\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg","keywords":["sindical"],"articleSection":["Not\u00edcias"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/","url":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/","name":"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer - FENATI","isPartOf":{"@id":"https:\/\/homolog.fenati.org.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#primaryimage"},"image":{"@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2026\/03\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg","datePublished":"2026-03-27T18:12:46+00:00","dateModified":"2026-03-27T20:57:49+00:00","breadcrumb":{"@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#primaryimage","url":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2026\/03\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg","contentUrl":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2026\/03\/brasil-producao-imunoterapia-40-tipos-de-cancer.jpg","width":1200,"height":630,"caption":"brasil-producao-imunoterapia-40-tipos-de-cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/homolog.fenati.org.br\/brasil-producao-imunoterapia-40-tipos-de-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/homolog.fenati.org.br\/"},{"@type":"ListItem","position":2,"name":"Brasil ter\u00e1 produ\u00e7\u00e3o de imunoterapia para 40 tipos de c\u00e2ncer"}]},{"@type":"WebSite","@id":"https:\/\/homolog.fenati.org.br\/#website","url":"https:\/\/homolog.fenati.org.br\/","name":"FEITTINF","description":"Federa\u00e7\u00e3o Nacional dos Trabalhadores em Tecnologia da\u00a0Informa\u00e7\u00e3o","publisher":{"@id":"https:\/\/homolog.fenati.org.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/homolog.fenati.org.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/homolog.fenati.org.br\/#organization","name":"FEITTINF","url":"https:\/\/homolog.fenati.org.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/homolog.fenati.org.br\/#\/schema\/logo\/image\/","url":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2023\/08\/logo_300x50.png","contentUrl":"https:\/\/homolog.fenati.org.br\/wp-content\/uploads\/2023\/08\/logo_300x50.png","width":350,"height":50,"caption":"FEITTINF"},"image":{"@id":"https:\/\/homolog.fenati.org.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/feittinf","https:\/\/x.com\/FederacaoTiBR","https:\/\/www.instagram.com\/feittinf\/"]},{"@type":"Person","@id":"https:\/\/homolog.fenati.org.br\/#\/schema\/person\/9ec09616199ae378090b2808cc903eae","name":"Pedro Carneiro","url":"https:\/\/homolog.fenati.org.br\/en\/author\/pedro-carneiro\/"}]}},"_links":{"self":[{"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/posts\/16880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/comments?post=16880"}],"version-history":[{"count":1,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/posts\/16880\/revisions"}],"predecessor-version":[{"id":16883,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/posts\/16880\/revisions\/16883"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/media\/16882"}],"wp:attachment":[{"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/media?parent=16880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/categories?post=16880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/homolog.fenati.org.br\/en\/wp-json\/wp\/v2\/tags?post=16880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}